Arctic Bioscience (Buy, TP: NOK60.00) - Moving forward as planned
Arctic Bioscience reported H1 earnings on 26 August. The company is moving in the right direction and is on track to start the phase IIb trial in mild/moderate psoriasis in Q1 2022. Sales trends for its nutraceuticals are on track as is its new production facility in Ørsta. The burn rate was in line with previous guidance and the company reiterated all guidance comments for this year. We reiterate our BUY and NOK60 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.